Abstract: Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.

Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.

Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:

Abstract: The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections.

Abstract: The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.

Abstract: This invention relates to the use of a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound 1,3,5,7-tetrahydroxy-8-isoprenylxanthone (TI, FIG. 1), that is naturally occurring in the plant of Garcinia esculenta Y. H. Li, and its biological activity of inhibiting nitric oxide production and microRNA 155 expression in stimulated macrophages, which can be developed as potential anti-inflammatory drugs.

Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.

Abstract: Methods are provided for forming a xanthone derivative via reacting a 2-substituted benzaldehyde with a phenol derivative to form the xanthone derivative.

Abstract: The invention discloses a new use of ?-Mangostin in medicine, which is application of ?-Mangostin in preparation of medicaments for Alzheimer's disease. Under the new working concentration, ?-Mangostin showed the capability to inhibit the aggregation and deposition of A?. Moreover, it displayed the neuroprotective effect against neurotoxicity caused by A? oligomer, which maintained normal morphology of mammalian neuron cells, enhanced their normal physiological function, and realized the intervention in pathological process of Alzheimer's disease. The invention provided a new approach to treat Alzheimer's disease.

Abstract: The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample.

Abstract: An organic light-emitting device that realizes high-emission efficiency and low-driving voltage is provided. The organic light-emitting device contains a xanthone compound represented by general formula [1].

Abstract: The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.

Abstract: A process for the production of ?-mangostin comprising the steps of preparing O-methyl ?-mangostin preferably from plants, subjecting the pure or partially pure O-methylated ?-mangostin to demethylation reaction procedure followed by purification of the said demethylated product to obtain pure ?-mangostin.

Abstract: A method of preparation of 5,6-dimethylxanthone-4-acetic acid (DMXAA) and derivatives thereof. The derivatives are represented by formula (I), wherein R represents totally 1 to 2 substitutes at 1, 2, 3, 7, and 8 position selected from a lower alkyl, halogen, CF3, CN, NO2, NH2, CH2COOH, OR2, OH, NHSO2R2, SR2, CH2CONHR2 or NHR2, and R2 represents a lower alkyl, or a lower alkyl having OH, NH2, or OCH3. The invention further provides a pharmaceutical composition having such derivatives used as excellent antitumor and antibacterial agents.

Abstract: The present invention relates to a UV irradiation assisted method of surface modification, which comprises: introducing a functional group L onto the surface of a polymer material P through the photochemical reaction of a photosensitive group X under UV irradiation, wherein the photosensitive group X comprises at least one xanthone unit.

Abstract: Na/K-ATPase/Src ligands, assays and uses thereof are disclosed.

Abstract: Cell permeable metal ion indicator compounds and methods of their use and synthesis are described. The compound comprises a metal chelating moiety (Mc), a reporter molecule and two or more lipophilic groups (GL) covalently bonded through a linker to the reporter molecule, wherein the lipophilic groups, when present in a live cell, are cleaved resulting in two or more negatively charged groups.

Abstract: The present invention relates to xanthone compounds isolated from the plant Psorospermum molluscum Hochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.

Abstract: The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.

Abstract: In one embodiment of the present invention, a composition is disclosed for measuring a binding affinity between a nucleic acid and a test substance, which contains an organic fluorescent substance capable of binding to an RNA and which emits fluorescence having an intensity greater while the organic fluorescent substance is liberated from an RNA than while the organic fluorescent substance is bound to an RNA. This enables a highly accurate and easy measurement of a binding affinity between a test substance and a nucleic acid, and allows various substances to be examined as a test substance.

Abstract: A biocompatible polymer composition suited to forming a dialysis membrane includes a matrix material and at least one xanthone. The composition may be formed into a membrane for inserting into a dialyzer filter whereby free radicals in the fluid are removed by the membrane.

Abstract: This invention relates to novel compounds that are xanthenone-4-acetic acid derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel xanthenone-4-acetic acid derivatives that are derivatives of AS 1404. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a vascular disrupting agent, such as AS 1404.

Abstract: The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject.

Abstract: Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar.

Abstract: The invention is directed to modified guanine-containing nucleosides and nucleotides and uses thereof. More specifically, the invention relates to modified fluorescently labelled guanine-containing nucleosides and nucleotides which exhibit enhanced fluorophore intensity by virtue of reduced quenching effects.

Abstract: A pharmaceutical composition having a cytotoxic effect to a cancer cell is provided. The pharmaceutical composition includes a flavonoid compound having a formula as wherein B ring is a 4-oxo-cyclohexa-2,5-dienyl group, and any one of R1-R12 is one selected from a group consisting of hydrogen group, hydroxyl group, C1-C20 alkyl group, C1-C20 ether group, C1-C20 ester group, carboxyl group, halogen and sugar. The flavonoid compound is obtained from a chemical method being one of a total synthesis method and a semi-synthesis method.

Abstract: A process for the production of ?-mangostin comprising the steps of preparing O-methyl ?-mangostin preferably from plants, subjecting the pure or partially pure O-methylated ?-mangostin to demethylation reaction procedure followed by purification of the said demethylated product to obtain pure ?-mangostin.

Abstract: The present invention relates to a heterocycle-containing onium salt useful as, for example, a cationic photopolymerization initiator and an acid generator for a chemically amplified resist, and provides a heterocycle-containing onium salt shown in the specification.

Abstract: The present invention relates to pharmaceutically stable crystalline forms of (5,6-Dimethyl-9-oxo-9H-xanthene-4-yl)acetic acid (DMXAA) sodium salt, processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those pharmaceutical compositions to treat tumours, optionally in combination with other active pharmaceutical agents.

Abstract: Aromatized A-ring derivatives of tetracycline compounds are described.

Abstract: The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample.

Abstract: The invention relates to novel nutraceutical and pharmaceutical compositions comprising at least a compound of the general formula (I), wherein R1 and R2 are independently from each other C1-8-alk(en)yl and R3 and R4 are independently from each other hydroxy or C1-8-alkyloxy, as well as to the use of these compositions for the treatment, co-treatment or prevention of joint disorders.

Abstract: The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample.

Abstract: Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for identification of compounds that rescue protein trafficking defects and methods of enhancing protein production.

Abstract: Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) wherein R1 through R3 and R5 through R11 are defined herein, and ?, ? and ? are optional bonds, providing that when ? is absent, ? is present, and when ? is absent, ? is present. When ? is present, preferred R4 moieties are selected from O, S, NH and CH2, and when ? is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When ? is present, the preferred R5 substituent is O, while when ? is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: The present invention refers to compounds of the general formulae I as defined above, preferably ?-mangostin, for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function and endurance. Other fields of use are eating disorders such as bulimia and anorexia nervosa, use for accelerating wound healing, and/or use for the treatment/prevention of bone disorders such as osteoporosis and osteopenia.

Abstract: The present invention provides a sulfonate compound including a structure represented by a general formula (I) below. In the formula (I), an atomic group A-O is an atomic group that forms a fluorescent compound upon cleavage of a covalent bond with a sulfonyl group. There may be one or plural atomic groups B—SO3— bound to an atomic group A. B is a ring substituted by one or plural electron-withdrawing groups. The electron-withdrawing group includes at least one selected from the group consisting of halogens, a carboxyl group, a carbamoyl group, a straight or branched alkylcarbamoyl group, a straight or branched alkanoyl group, a straight or branched alkoxycarbonyl group, a straight or branched alkyl halide group, and —NR3+ group (the three Rs each denote a hydrogen atom or a straight or branched alkyl group and may be the same or different). When there are plural Bs, the Bs may be the same or different.

Abstract: The present invention provides a sulfonate compound, including a structure represented by a general formula (I) below, where, in the formula (I), an atomic group A-O is an atomic group that forms a fluorescent compound upon cleavage of a covalent bond between the atomic group A-O and a sulfonyl group, one or a plurality of atomic groups B—SO3— are bonded to an atomic group A, B is a ring that is substituted by one or a plurality of electron-withdrawing groups, the electron-withdrawing group is at least one selected from the group consisting of an alkyl halide group, a nitro group and a cyano group, and B may be the same or different in kind in the case where the plurality of B exist.

Abstract: The present invention discloses morusin, a method of extracting morusin, as well as various uses in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses.

Abstract: The present invention is directed to an improved process for producing substantially pure fluorescein, as well as to substantially pure fluorescein compositions prepared by the process. The invention is particularly directed to the provision of pharmaceutical compositions for use in angiography. The substantially pure fluorescein produced by the process of the present invention is low in color, low in sodium chloride content, and substantially free of pyridine.

Abstract: The present invention discloses sulfonamide A-(Q)n—Ar—SChNHR which are CA IX-selective inhibitors, which selectively bind to the enzyme under hypoxic conditions and are able to reverse the tumor acidification mediated by the enzyme. These compounds are useful in anticancer therapies based on tumor-associated CA isozyme inhibition as well as for hypoxic tumor imaging.

Abstract: Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) wherein R1 through R3 and R5 through R11 are defined herein, and ?, ?, and ? are optional bonds, providing that when ? is absent, ? is present, and when ? is absent, ? is present. When ? is present, preferred R4 moieties are selected from O, S, NH and CH2, and when ? is absent, preferred R4 groups are selected from OH, SH, NH2 and CH3. When ? is present, the preferred R5 substituent is O, while when ? is absent, the preferred R5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

Abstract: The present invention relates to a heterocycle-containing onium salt useful as, for example, a cationic photopolymerization initiator and an acid generator for a chemically amplified resist, and provides “a heterocycle-containing onium salt shown in the specification.

Abstract: Psorospermin is a cytotoxic dihydroflranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin analogs to inhibit cellular proliferation.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.

Abstract: The present invention relates to compounds of formula (I) 1

Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.

Abstract: To provide a semaphorin inhibitor; a peripheral or central nerve regeneration promoter which contains said semaphorin inhibitor as an active ingredient; and a preventive or remedy for a neuropathic disease and a neurodegenerative disease containing said nerve regeneration promoter, or the like.